Healthcare Services

A Significant Growth Driver for the Hepatitis D Market Is the Rising Hepatitis B Prevalence Fuels Growth In The Market

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Hepatitis D Market Between 2026 And 2030?

The hepatitis d market size has shown consistent expansion over recent years. Its projected growth will see it rise from $0.76 billion in 2025 to $0.79 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.4%. This historical progression can be ascribed to several factors, including enhanced hepatitis B screening coverage, a greater acknowledgment of HDV severity, broadened diagnostic capabilities, an increase in referrals to specialty centers, and the introduction of targeted therapies.

The hepatitis d market is projected to experience consistent expansion over the upcoming years. By 2030, its value is anticipated to reach $0.93 billion, demonstrating a compound annual growth rate (CAGR) of 4.1%. This projected growth is driven by several factors, including intensified research into innovative HDV therapies, a heightened emphasis on combined antiviral treatments, the expansion of prevention approaches linked to vaccination, increasing understanding among at-risk demographics, and greater financial commitments to investigating rare liver diseases. Key trends anticipated during this period encompass a stronger emphasis on identifying co-infections early, more widespread adoption of advanced serologic diagnostic methods, a rising need for tailored treatment regimens, the expansion of hospital-centric disease management programs, and a heightened commitment to increasing disease awareness.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21202&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Hepatitis D Market?

The rising occurrence of hepatitis B is anticipated to drive expansion in the hepatitis D market in the future. Hepatitis B is defined as a viral ailment impacting the liver, manifesting symptoms like jaundice, tiredness, and stomach discomfort, and has the potential to progress to chronic liver conditions or liver cancer without intervention. The surge in Hepatitis B instances stems from elements including unprotected intimate contact, the sharing of injection needles, transmission from mother to infant during delivery, and inadequate vaccination rates in specific locales. Hepatitis D depends on the Hepatitis B virus for its reproduction, utilizing Hepatitis B’s surface antigen to infiltrate liver cells, thereby establishing co-infection of these two viruses as a crucial element in the advancement of liver ailments. As an illustration, in April 2025, data from the Department of Health and Human Services, a US government agency, indicated 17,650 newly reported chronic hepatitis B cases and 1,769 hepatitis B-related fatalities were documented in 2023. Consequently, the expanding occurrence of hepatitis B is fueling the growth of the hepatitis D market.

Which Market Segments Are Examined In The Hepatitis D Market Study?

The hepatitis d market covered in this report is segmented –

1) By Type: Acute, Chronic

2) By Diagnosis: Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Other Diagnosis

3) By Distribution Channel: Hospital pharmacies, Retail pharmacies

4) By End-Users: Clinic, Hospital, Other End Users

Subsegments:

1) By Acute: Self-limiting Acute Hepatitis D, Severe Acute Hepatitis D

2) By Chronic: Compensated Chronic Hepatitis D, Decompensated Chronic Hepatitis D

What Trends Are Affecting The Expansion Of The Hepatitis D Market?

Leading companies in the hepatitis D market are prioritizing the development of innovative solutions, such as RNA-targeted antiviral therapy, to improve treatment outcomes and address the unmet medical needs in chronic hepatitis D infection. RNA-targeted antiviral therapy describes a therapeutic approach that directly targets a virus’s RNA to inhibit its replication, disrupt viral protein production, or silence viral genes, thereby reducing the viral load and controlling the infection. For instance, in December 2024, Vir Biotechnology Inc., a US-based biotechnology company, obtained both the U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and the European Medicines Agency (EMA) Priority Medicines (PRIME) designation for its combination therapy of tobevibart and elebsiran, used in treating chronic hepatitis delta (CHD).

Who Are The Primary Competitors In The Hepatitis D Market?

Major companies operating in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc., VBI Vaccines Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A., Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc., Bluejay Therapeutics Inc., Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc., Biorex Diagnostics Ltd.

Read the full hepatitis d market report here:

https://www.thebusinessresearchcompany.com/report/hepatitis-d-global-market-report

What Are The Leading Geographic Regions In The Hepatitis D Market?

North America was the largest region in the hepatitis D market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis d market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Hepatitis D Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21202&type=smp

Browse Through More Reports Similar to the Global Hepatitis D Market 2026, By The Business Research Company

Viral Hepatitis Global Market Report

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Vitamin D Global Market Report

https://www.thebusinessresearchcompany.com/report/vitamin-d-global-market-report

Hepatitis C Global Market Report

https://www.thebusinessresearchcompany.com/report/hepatitis-c-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795